Chemotherapy and Metastasis: New Insights in Genitourinary Cancers
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 3605
Special Issue Editors
Interests: prostate cancer; cell migration; invasion; metastasis; G-protein subunit; lamellipodia; small molecule inhibitors; chemotherapeutic drugs
Interests: prostate cancer; cancer biology (initiation, progression, and metastases); tumor microenvironment; cancer health disparity; cancer genomics; translational oncology; drug resistance
Special Issue Information
Dear Colleagues,
The first approach during cancer treatment is usually surgery, accompanied or anticipated by the use of chemotherapeutic drugs. Depending on the cancer type and the stage of the disease, these treatments may be considered effective and curative. However, it is very common in cancer patients, despite achieving complete control of the primary tumor, to developme a distant metastasis, which represents a high risk of mortality. Traditionally, we have defined metastasis as an undetectable cancer foci, already present at the time of initial treatment, but it has been shown that it is not only that. Recent studies have shown that chemotherapy can also increase the capability of cancer cells to escape from death and migrate to a distant site to form a metastasis. In addition, epidemiological studies show that the increase in incidence and mortality rate of certain genitourinary cancers are linked to racial health disparities. Certain racial populations develop more advanced and aggressive forms of cancers, specifically men as it relates to prostate cancer. The major challenge in treating patients with advanced disease is therapeutic resistance to the current therapies, including chemotherapy. Overriding this resistance requires an understanding of the driving mechanisms of the tumor microenvironment and the molecular differences that play a role in cancer health disparities. For these reasons, we are interested in a more detailed understanding of how chemotherapeutic drugs can induce an increase in metastasis formation and if helth disparities can play a role in these events, especially in genitourinary cancers.
Dr. Silvia Caggia
Dr. Bethtrice Thompson Elliott
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer metastasis
- chemotherapy
- prostate cancer
- bladder cancer
- kidney cancer
- urethral cancer
- RNA seq
- TGF signaling
- health disparities
